Search Results - "Dunn, J.A."

11LBA Differences in the quality of life (QoL) and functional outcomes of treatment between HPV associated (HPV+) and HPV- patients receiving primary chemoradiotherapy in PET-NECK - a multi-centre randomized phase III controlled trial (RCT) comparing PETCT guided active surveillance with planned neck dissection (ND) for locally advanced (N2/N3) nodal metastases (LANM) in patients with head and neck squamous cell cancer (HNC) treated with primary radical chemoradiotherapy (CRT) by Mehanna, H, Wong, W.L, McConkey, C.C, Rahman, J.K, Robinson, M, Hartley, A, Nutting, C, Powell, N, Al-Booz, H, Junor, E, Hulme, C, Smith, A.F, Hall, P, Dunn, J.A

Get full text

OC-11 - Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism by Young, A, Phillips, J, Hancocks, H, Hill, C, Joshi, N, Marshall, A, Grumett, J, Dunn, J.A, Lokare, A, Chapman, O

“…Introduction Venous thromboembolism (VTE) in cancer patients is an increasingly frequent clinical problem. The overall impact of VTE on cancer patients can be…”
Get full text

1809 Results of the OPTIMA (Optimal Personalized Treatment of early breast cancer usIng Multi-parameter Analysis) prelim study by Stein, R.C, Makris, A, Hughes-Davies, L, Bartlett, J.M.S, Marshall, A, Hall, P.S, Campbell, A, Pinder, S.E, Cameron, D.A, Rea, D, Earl, H, MacPherson, I, Poole, C, Canney, P, Francis, A, Morgan, A, Stallard, N, Hulme, C, McCabe, C, Dunn, J.A

Get full text

A Randomised Controlled Trial to Evaluate both the Role and the Optimal Fractionation of Radiotherapy in the Conservative Management of Early Breast Cancer by Spooner, D, Stocken, D.D, Jordan, S, Bathers, S, Dunn, J.A, Jevons, C, Dodson, L, Morrison, J.M, Oates, G.D, Grieve, R.J

“…Abstract Aims Postoperative radiotherapy is routinely used in early breast cancer employing either 50 Gy in 25 daily fractions (long course) or 40 Gy in 15…”
Get full text

Follow-up in Early Breast Cancer — A Surgical and Radiological Perceptive by Dunn, J.A, Donnelly, P.K, Marshall, A, Wilcox, M, Watson, E, Young, A, Balmer, C, Ramirez, M, Hartup, S, Maxwell, A.J, Evans, A.J

Get full text

Comparing the Simulator with the Live Patient Model in the ATLS® Initial Assessment Station by Ali, J, Dunn, J.A, Eason, M.P, Drumm, J.L

Get full text

The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-up by Hallissey, M T, Dunn, J A, Ward, L C, Allum, W H

“…The overall survival in patients with gastric cancer is low, even among those undergoing resection. It has been hoped that the development of adjuvant therapy…”
Get more information

Influence of surgical resection and post-operative complications on survival following adjuvant treatment for pancreatic cancer in the ESPAC-1 randomized controlled trial by Bassi, C, Stocken, D D, Olah, A, Friess, H, Buckels, J, Hickey, H, Dervenis, C, Dunn, J A, Deakin, M, Carter, R, Ghaneh, P, Neoptolemos, J P, Buchler, M W

“…The influence of type of surgery and occurrence of post-operative complications on survival following adjuvant therapy for pancreatic cancer are uncertain. Cox…”
Get more information

Rapid method for the detection of storage mites in cereals: feasibility of an ELISA based approach by Dunn, J A, Thind, B B, Danks, C, Chambers, J

“…This paper describes the development of rapid immunodiagnostic tests for the detection of storage mite infestations in cereals and cereal products. The study's…”
Get more information

Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma by Lee, R.J., Gremel, G., Marshall, A., Myers, K.A., Fisher, N., Dunn, J.A., Dhomen, N., Corrie, P.G., Middleton, M.R., Lorigan, P., Marais, R.

“…Patients with high-risk stage II/III resected melanoma commonly develop distant metastases. At present, we cannot differentiate between patients who will recur…”
Get full text

Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients by Ali, H.R., Provenzano, E., Dawson, S.-J., Blows, F.M., Liu, B., Shah, M., Earl, H.M., Poole, C.J., Hiller, L., Dunn, J.A., Bowden, S.J., Twelves, C., Bartlett, J.M.S., Mahmoud, S.M.A., Rakha, E., Ellis, I.O., Liu, S., Gao, D., Nielsen, T.O., Pharoah, P.D.P., Caldas, C.

“…T-cell infiltration in estrogen receptor (ER)-negative breast tumours has been associated with longer survival. To investigate this association and the…”
Get full text

Commentary on: Introduction of an abbreviated breast MRI service in the UK as part of the BRAID trial: practicalities, challenges, and future directions by Jones, L.I., Dunn, J.A.

Get full text

LBA11 Individual patient data meta-analysis of 5 non-inferiority RCTs of reduced duration single agent adjuvant trastuzumab in the treatment of HER2 positive early breast cancer by Earl, H.M., Hiller, L., Dunn, J.A., Conte, P.F., D'Amico, R., Guarneri, V., Joensuu, H., Huttunen, T., Georgoulias, V., Abraham, J., Cameron, D., Miles, D.W., Wardley, A.M., Romieu, G., Debled, M., Faure-Mercier, C., Lindman, H., Fraser, J., Cox, D., Pivot, X.

Get full text

O-110 The challenges of using radiological ‘tumour response’ as an endpoint in Neo-tAnGo: a national neo-adjuvant chemotherapy breast cancer trial by Hiller, L, Fenwick, N, Vallier, A.L, Dunn, J.A, Hilborne, S, Jones, L, Abraham, J, Iddawela, M, Caldas, C, Earl, H.M

Get full text

Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial by Corrie, P.G., Marshall, A., Nathan, P.D., Lorigan, P., Gore, M., Tahir, S., Faust, G., Kelly, C.G., Marples, M., Danson, S.J., Marshall, E., Board, R.E., Waterston, A.M., Nobes, J.P., Harries, M., Kumar, S., Goodman, A., Dalgleish, A., Martin-Clavijo, A., Westwell, S., Casasola, R., Chao, D., Patel, P.M., Ottensmeier, C.H., Farrugia, D., Eccles, B., Young, G., Barker, E.O., Harman, C., Weiss, M., Myers, K.A., Chhabra, A., Rodwell, S.H., Dunn, J.A., Middleton, M.R., Nathan, Paul, Lorigan, Paul, Dziewulski, Peter, Holikova, Sonja, Panwar, Udaiveer, Tahir, Saad, Faust, Guy, Thomas, Anne, Corrie, Pippa, Sirohi, Bhawna, Kelly, Charles, Middleton, Mark, Marples, Maria, Danson, Sarah, Lester, James, Marshall, Ernest, Ajaz, Mazhar, Houston, Stephen, Board, Ruth, Eaton, David, Waterston, Ashita, Nobes, Jenny, Loo, Suat, Gray, Gill, Stubbings, Helen, Gore, Martin, Harries, Mark, Kumar, Satish, Goodman, Andrew, Dalgleish, Angus, Martin-Clavijo, Agustin, Marsden, Jerry, Westwell, Sarah, Casasola, Richard, Chao, David, Maraveyas, Anthony, Patel, Poulam, Ottensmeier, Christian, Farrugia, David, Humphreys, Alison, Eccles, Bryony, Herbert, Chris, Price, Christopher, Brunt, Murray, Scott-Brown, Martin, Hamilton, Joanna, Hayward, Richard Larry, Smyth, John, Woodings, Pamela, Nayak, Neena, Burrows, Lorna, Wolstenholme, Virginia, Wagstaff, John, Nicolson, Marianne, Wilson, Andrew, Barlow, Clare, Scrase, Christopher, Podd, Timothy, Gonzalez, Michael, Highley, Martin, Grumett, Simon, Talbot, Toby, Nathan, Kannon, Coltart, Robert, Gee, Bruce

“…Bevacizumab is a recombinant humanised monoclonal antibody to vascular endothelial growth factor shown to improve survival in advanced solid cancers. We…”
Get full text

PO-36 Treatment of cancer-associated venous thromboembolism: 12-month outcomes of the placebo versus rivaroxaban randomisation of the SELECT-D trial by Marshall, A., Young, A.M., Levine, M., Hill, C., Hale, D., Thirlwall, J., Wilkie, V., French, K., Kakkar, A.K., Lokare, A., Maraveyas, A., Chapman, O., Arif, A., Petrou, S., Maredza, M., Hobbs, F.D.R., Dunn, J.A.

Get full text

Cost-effectiveness analysis of PET-CT-guided management for locally advanced head and neck cancer by Smith, A.F., Hall, P.S., Hulme, C.T., Dunn, J.A., McConkey, C.C., Rahman, J.K., McCabe, C., Mehanna, H.

“…A recent large United Kingdom (UK) clinical trial demonstrated that positron-emission tomography–computed tomography (PET-CT)-guided administration of neck…”
Get full text

The potential utility of abbreviated breast MRI (FAST MRI) as a tool for breast cancer screening: a systematic review and meta-analysis by Geach, R., Jones, L.I., Harding, S.A., Marshall, A., Taylor-Phillips, S., McKeown-Keegan, S., Dunn, J.A., Kuhl, Christiane, Vinnicombe, Sarah, O'Flynn, Elizabeth, Wookey, Jennifer, Rose, Janice, Foy, Christopher, Taylor, Victoria, Valencia, Alexandra, Gifford, John, Gray, Rosie, Jones, Thomas William, Litton, Karen, Lloyd, Simon, Kutt, Elisabeth, Pocklington, Alice, Mahatma, Anjum, Massey, Helen, Clark, Gillian, McLachlan, Clare, Beckett, Gemini, Alison, Clare, Barta, Miklos, Betancourt, Claudia, Bramwell, Julie, Bright, Nichola, Burt, Helen, Cann, Louise, Ceney, Jane, Cornford, Eleanor, Dalgliesh, Diana, Doyle, Sarah, Fearn, Sarah, Godden, Dagmar, Goldthorpe, Zoe, Hobson, Lucinda, Hynam, Paula, Jackson, Emma, Jenkin, Margaret, Kingsnorth, Beckie, Klimczak, Katherine, Moody, Alice, Perrin, Sarah, Peters, Alison, Preston, Elizabeth, Ratsey, Anne, Sidebottom, Richard, Steel, Jim, Stephenson, Lesley, Taylor, Michelle, Toth, Erika, Vincent, Frances, Watkin, Sharon, Widdison, Sue, Williams, Jennifer, Wilmot, Karen, Elangovan, Premkumar, Halling-Brown, Mark, Ghiasvand, Hesam, Hulme, Claire, Singamaneni, Sravya, Friedrich, Zsolt, Robson, Joanne, Mankelow, Anna

“…To synthesise evidence comparing abbreviated breast magnetic resonance imaging (abMRI) to full-protocol MRI (fpMRI) in breast cancer screening. A systematic…”
Get full text

Anticoagulation Therapy in SELECTeD Cancer Patients at Risk of Recurrence of Venous Thromboembolism: Results of the ‘select-d’ Pilot Trial by Young, A., Marshall, A., Thirlwall, J., Chapman, O., Lokare, A., Hill, C., Hale, D., Dunn, J.A., Kakkar, A.K., Levine, M.

Get full text

Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial by Earl, H.M., Hiller, L., Dunn, J.A., Blenkinsop, C., Grybowicz, L., Vallier, A.-L., Gounaris, I., Abraham, J.E., Hughes-Davies, L., McAdam, K., Chan, S., Ahmad, R., Hickish, T., Rea, D., Caldas, C., Bartlett, J.M.S., Cameron, D.A., Provenzano, E., Thomas, J., Hayward, R.L.

“…The ARTemis trial previously reported that addition of neoadjuvant bevacizumab (Bev) to docetaxel (D) followed by fluorouracil, epirubicin and cyclophosphamide…”
Get full text